28. 全身性アミロイドーシス Systemic amyloidosis Clinical trials / Disease details
臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04298372 (ClinicalTrials.gov) | February 20, 2019 | 3/12/2019 | Frontline Lenalidomide for AL Amyloidosis Involving Myocardium | Frontline Lenalidomide for AL Amyloidosis Involving Myocardium: Investigation of Organ Reversing Capacity of Lenalidomide | Amyloidosis Cardiac | Drug: Lenalidomide 25mg | Seoul National University Hospital | NULL | Recruiting | 19 Years | 99 Years | All | 30 | Phase 3 | Korea, Republic of |